If You Invested in XOMA Royalty Corporation (XOMAO)

XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (Nasdaq: XOMAO) represent depositary shares, each corresponding to a fractional interest in XOMA Royalty Corporation’s 8.375% Series B Cumulative Perpetual Preferred Stock. XOMA Royalty Corporation is described in its public communications as a biotechnology royalty aggregator that focuses on economic interests in pharmaceutical and biotechnology assets.

According to multiple company press releases, XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires these future economic rights, the seller receives non-dilutive, non-recourse funding that can be used to advance internal drug candidates or for general corporate purposes. The company characterizes its holdings as an extensive and growing portfolio of assets, where an asset is defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate.

The XOMAO preferred stock depositary shares are tied to this business model. Holders of these depositary shares have an interest in the 8.375% Series B Cumulative Perpetual Preferred Stock. In its dividend announcements, XOMA Royalty notes that these preferred shares are cumulative, meaning authorized dividends accumulate if not paid when scheduled, and are intended to provide a defined dividend rate to holders of the depositary shares representing the Series B preferred stock.

Press releases describe XOMA Royalty as playing a distinctive role in helping biotech companies achieve their goal of improving human health. Instead of developing and commercializing drugs directly, XOMA Royalty focuses on acquiring milestone and royalty rights associated with therapeutic candidates that are in development or already commercialized by partner companies. These rights can be linked to a range of programs, including early-stage and late-stage clinical assets, and commercial products.

In its communications, XOMA Royalty explains that its portfolio refers strictly to milestone and/or royalty rights associated with a basket of drug products in development, and its assets refer to milestone and/or royalty rights associated with individual drug products in development. The company has disclosed that its commercial milestone and royalty portfolio includes assets such as VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY [coagulation factor IX (recombinant)], and DSUVIA (sufentanil sublingual tablet). Other assets in the portfolio are described as investigational compounds, for which efficacy and safety have not been established and there is no guarantee of eventual commercial availability.

Company updates also highlight that XOMA Royalty pursues royalty sharing and acquisition transactions with large pharmaceutical partners. For example, the company has reported amending a collaboration with Takeda through a strategic royalty share transaction, where Takeda’s royalty and milestone payment obligations related to mezagitamab were adjusted, and XOMA Royalty became entitled to payments based on a share of milestones and royalties associated with a group of development-stage assets in Takeda’s externalized assets portfolio. These types of transactions illustrate how XOMA Royalty seeks to diversify its royalty and milestone exposure across multiple therapeutic programs.

In addition to acquiring royalty interests, XOMA Royalty has announced corporate acquisitions of biotechnology companies whose pipelines and partnered programs can add to its royalty and milestone portfolio. Recent press releases describe completed acquisitions of entities such as HilleVax, LAVA Therapeutics, and Mural Oncology through tender offers or schemes of arrangement. Following these transactions, the acquired companies became wholly owned subsidiaries of XOMA Royalty, and their shares were delisted from Nasdaq.

From a capital structure perspective, XOMA Royalty has communicated that its Board of Directors periodically authorizes cash dividends to holders of its Series A and Series B Cumulative Perpetual Preferred Stock, including the depositary shares traded under XOMAO. These announcements specify the per-share dividend amounts for the preferred series and the relevant record and payment dates. This underscores that XOMAO is designed as an income-oriented security within the broader context of XOMA Royalty’s royalty-focused business model.

Operationally, XOMA Royalty emphasizes business development activities that secure economic interests in partnered assets. Press releases describe transactions that provide XOMA Royalty with royalty or milestone entitlements on programs being developed by partners such as Pfizer, Johnson & Johnson, Mirum Pharmaceuticals, Oak Hill Bio, Recursion Pharmaceuticals, and others. The company notes that these arrangements can span a range of therapeutic areas and development stages, including neuropsychiatric disorders, rare diseases, oncology, and other conditions where there is perceived unmet medical need.

Financial updates from XOMA Royalty highlight that it receives royalties and milestone payments from its partners based on commercial sales and development progress of underlying products. The company has reported royalty receipts and milestone income over multi-quarter periods, and has indicated that growing royalty receipts reflect commercial execution by its partners. These disclosures also reference the potential for future clinical readouts and regulatory milestones related to programs within its portfolio.

In summary, XOMA Royalty Corporation’s 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares (XOMAO) are linked to a company that positions itself as a biotechnology royalty aggregator. XOMA Royalty’s stated strategy is to acquire future economic rights—royalties and milestones—associated with therapeutic candidates licensed to pharmaceutical and biotechnology companies, providing non-dilutive, non-recourse funding to those counterparties. The preferred stock represented by XOMAO participates in this structure through a defined dividend rate and cumulative feature, while the underlying company continues to expand and manage a portfolio of royalty and milestone interests across commercial and development-stage biopharmaceutical assets.

Key characteristics of XOMAO and XOMA Royalty

• Security type: Depositary shares, each representing a fractional interest in XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock, as described in dividend announcements.
• Dividend feature: Cumulative preferred dividends authorized periodically by XOMA Royalty’s Board of Directors for Series B preferred stock depositary shares.
• Business focus: Biotechnology royalty aggregation, centered on acquiring future economic rights to pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies.
• Funding model for partners: Non-dilutive, non-recourse funding to sellers in exchange for future economic rights, according to company press releases.
• Portfolio definition: Portfolio refers to milestone and/or royalty rights associated with a basket of drug products in development; assets refer to milestone and/or royalty rights associated with individual drug products in development.
• Commercial portfolio examples: Royalty and milestone interests associated with products such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, as disclosed in dividend-related press releases.
• Growth strategy: Expansion and diversification of royalty and milestone rights through collaborations, royalty-sharing transactions, and acquisitions of companies with partnered or proprietary pipelines.

How XOMA Royalty positions itself in the biotech ecosystem

In its public statements, XOMA Royalty describes itself as occupying a specific niche within the healthcare ecosystem: it focuses on royalty and milestone economics rather than direct drug development. By acquiring rights to future economics from a broad set of underlying therapeutic candidates, XOMA Royalty aims to build a diversified stream of potential royalty and milestone payments. This approach is presented as beneficial both to XOMA Royalty and to the counterparties that receive funding while retaining operational control of their programs.

For investors evaluating XOMAO, the preferred stock depositary shares represent an instrument linked to this royalty-focused business model, with defined dividend terms on the Series B preferred stock and exposure to XOMA Royalty’s portfolio of royalty and milestone interests as described in its press releases.